Osimert 80 mg is a tablet containing 80 mg of osimertinib, an EGFR tyrosine kinase inhibitor used in selected patients with EGFR-mutated non-small cell lung cancer (NSCLC).

Osimertinib is a targeted cancer medicine that irreversibly inhibits mutant EGFR, including selected sensitizing mutations and the T790M resistance mutation.

Osimert 80 mg is used in specific EGFR-mutated NSCLC treatment settings. Approved uses and treatment requirements can vary between countries.

The U.S. labeled adult dose for the principal approved indications is 80 mg once daily. The appropriate dose and treatment duration should be determined by the prescribing healthcare professional.

Yes. The U.S. prescribing information permits the 80 mg tablet to be taken with or without food.

The U.S. prescribing information advises not to make up a missed dose. The next dose should be taken at the scheduled time.

Common adverse effects can include diarrhea, rash, dry skin, nail toxicity, stomatitis, fatigue and changes in certain blood-cell counts. Not every patient experiences these effects.

Serious risks include interstitial lung disease or pneumonitis, QTc prolongation, cardiomyopathy, keratitis, severe skin reactions, cutaneous vasculitis, aplastic anemia and fetal toxicity.

Yes. QTc prolongation and cardiomyopathy are recognized risks. Patients with relevant risk factors may require ECG and cardiac-function monitoring as directed by their healthcare professional.

Yes. Osimertinib can cause interstitial lung disease or pneumonitis, which can be serious or fatal. New or worsening breathing symptoms should receive prompt medical evaluation.

Osimertinib has meaningful penetration into the central nervous system and has demonstrated intracranial activity in patients with EGFR-mutated NSCLC.

T790M is a secondary EGFR mutation that can cause resistance to earlier EGFR tyrosine kinase inhibitors. Osimertinib was developed to target this resistance mutation as well as other clinically relevant mutant forms of EGFR.

Osimert and Tagrisso contain the same active ingredient, osimertinib, but they are different branded products. Osimert is associated with Everest Pharmaceuticals, while Tagrisso is the reference product developed and marketed by AstraZeneca.

Everest Pharmaceuticals Ltd. lists Osimert 80 mg as an osimertinib product in its official product catalogue.

Everest Pharmaceuticals operates an official E-Verification system that allows an eligible product code to be checked. Product packaging, batch information and expiry information should also be reviewed carefully.

Osimertinib can cause fetal harm. Pregnancy, contraception and reproductive considerations should be discussed with the treating healthcare professional before and during treatment.

Patients should not independently stop or alter cancer treatment because of side effects. The treating healthcare professional should determine whether treatment should continue, be interrupted, reduced or permanently discontinued.

Osimertinib should not be described as a guaranteed cure. Clinical outcomes vary according to disease stage, tumor genetics, treatment setting, previous treatment and individual patient factors.

Osimertinib is a targeted EGFR tyrosine kinase inhibitor rather than a conventional cytotoxic chemotherapy medicine. In certain approved treatment settings, it may be prescribed together with chemotherapy.